Phase 1 N=16 Psilocybin-assisted CBT for Depression
Major Depressive Disorder
Primary: Treatment Acceptability (Client Satisfaction Questionnaire-8) — 30.8 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=11 Therapeutic Intervention Supporting Development From NICU to 6 Months for Infants Post Hypoxic-Ischemic Encephalopathy
Cerebral Palsy · Hypoxic-Ischemic Encephalopathy
Primary: Feasibility of the Neonatal Intensive Care Unit Component of the Intervention. — 0; 1 Participants
N/A N=78 Evaluation of the Effects of Intraoperative Ventilation Modes on Perioperative Atelectasis
Atelectasis, Postoperative Pulmonary
Primary: Change in Lung Ultrasound Score (ΔLUS) From Preoperative Baseline to 24 Hours Postoperatively — 4.92; 3.88; 5.20 scores on a scale — p=0.131
N/A N=33 Smartphone App-guided Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure
Blood Pressure · Vascular Function · Adherence, Treatment
Primary: Change From Baseline in Casual Systolic Blood Pressure — -2; 0 mmHg
Phase 3 N=156 Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Relapsing-Remitting Multiple Sclerosis
Primary: Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans — 0.161; 0.049 proportion of…
N/A N=98 A Peer-Driven Intervention to Increase PrEP Uptake Among Minority MSM
HIV Infections
Primary: Pre-exposure Prophylaxis (PrEP) Uptake — 5; 13 Participants
N/A N=81 Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy
Clinical Trials · Immunotherapy
Primary: Acceptability of Intervention — 4.11 Score (1-5 scale)
N/A N=1,514 BENLYSTA® Special Drug Use Investigation
Systemic Lupus Erythematosus
Primary: Number of Participants With Adverse Drug Reactions (ADRs) — 107; 110; 47; 0 Participants
Phase 3 N=1,717 A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
Asthma
Primary: Annualized Rate of Clinically Significant Exacerbations Over 52 Weeks — 0.57; 0.49 Exacerbation per participant per year — p=0.079
Phase 2 N=96 Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease
Chronic Kidney Disease Stage 3 · Chronic Kidney Disease Stage 4
Primary: Change in Plasma 8 Isoprostane From Baseline — 19.2; 35.0; 18.1; 56.3 pg/mL
N/A N=224 To Evaluate Effectiveness and Safety of GP0109 for Jawline Definition
Jawline Definition Deficiency
Primary: Percentage of Responders Based on Blinded Evaluators' Live Assessment of the Galderma Jawline Scale (GJS) — 14.3; 85.1 percentage of participants — p=<0.001
N/A N=1,214 Vyndaqel Capsules Special Investigation (ATTR-CM)
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Number of Participants With Adverse Drug Reactions — 45; 7 Participants
Phase 2 N=41 A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
Primary: Plasma Concentration of Bimekizumab at Week 0 — NA; NA microgram per milliliter (µg/mL)
N/A N=102 Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease
Infrainguinal Peripheral Artery Disease · Peripheral Arterial Disease · PAD
Primary: Primary Efficacy: Acute Procedural Success — 69 Lesions
Phase 2 N=40 Psilocybin-facilitated Treatment for Cocaine Use
Cocaine-Related Disorders
Primary: Percentage of Abstinent Days — 97.43; 71.63; 98.11; 61.85 Percentage of abstinent days